Repeated interferon-α administration inhibits dopaminergic neural activity in the mouse brain

Brain Research

Volumn 747, Issue 2, 1997, Pages 348-351

  Shuto, Hideki ^a   Kataoka, Yasufumi ^a   Horikawa, Tomoko ^a   Fujihara, Narumi ^a   Oishi, Ryozo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

depression; dopamine; interferon ; parkinsonism; suicide; turnover

Indexed keywords

ALPHA INTERFERON; DIHYDROXYPHENYLACETIC ACID; DOPAMINE; NORADRENALIN; SEROTONIN;

ANIMAL EXPERIMENT; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; MALE; MOUSE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL;

ANIMALS; BIOGENIC MONOAMINES; BRAIN; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; INTERFERON-ALPHA; MALE; MICE; MICE, INBRED STRAINS; NOREPINEPHRINE; SEROTONIN; SYNAPTIC TRANSMISSION;

EID: 0031040003     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(96)01371-6     Document Type: Article

References (28)

1. Adams, F., Fernandez, F. and Mavligit, G., Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities, J. Neurooncol., 6 (1988) 355-359.
2. Adams, F., Quesada, J.R. and Gutterman, J.U., Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer, JAMA, 252 (1984) 938-941.
3. Barchas, J.D., Hamblin, M.W. and Malenka, R.C., Biochemical hypotheses of mood and anxiety disorders. In G.J. Siegel, B.W. Agranoff, R.W. Albers and P.B. Molinoff (Eds.), Basic Neurochemistry: Molecular, Cellular and Medical Aspects, Fifth Ed., Raven, New York, NY, 1994, pp. 984.
4. Blalock, J.E. and Smith, E.M., Human leukocyte interferon (HuIFN-α): potent endorphin-like opioid activity, Biochem. Biophys. Res. Commun., 101 (1981) 472-478.
5. Born, J., Späth-Schwalbe, E., Pietrowsky, R., Porzsolt, F. and Fehm, H.L., Neurophysiological effects of recombinant interferon-gamma and -alpha in man, Clin. Physiol Biochem., 7 (1989) 119-127.
6. Brodie, B.B., Costa, E., Dlabac, A., Neff, N.H. and Smookler, H.H., Application of steady state kinetics to the estimation of synthesis rate and turnover time of tissue catecholamines, J. Pharmacol. Exp. Ther., 154 (1966) 493-498.
7. Brown, A.S. and Gershon, S., Dopamine and depression, J. Neural. Transm., 91 (1993) 75-109.
8. Crnic, L.S. and Segall, M.A., Behavioral effects of mouse interferons-α and -γ and human interferon-α in mice, Brain Res., 590 (1992) 277-284.
9. Dafny, N., Prieto-Gomez, B. and Reyes-Vazquez, C., Does the immune system communicate with the central nervous system? Interferon modifies central nervous activity, J. Neuroimmunol., 9 (1985) 1-12.
10. De Sarro, G.B., Masuda, Y., Ascioti, C., Audino, M.G. and Nistico, G., Behavioural and ECoG spectrum changes induced by intracerebral infusion of interferons and interleukin 2 in rats are antagonized by noloxone, Neuropharmacology, 29 (1990) 167-179.
11. Dianzani, F., Antonelli, G. and Capobianchi, M.R., The biological basis for clinical use of interferon, J. Hepatol., 11 (1990) S5-S10.
12. Dinarello, C.A., Bernheim, H.A., Duff, G.W., Le, H.V., Nagabhushan, T.L., Hamilton, N.C. and Coceani, F., Mechanisms of fever induced by recombinant human interferon, J. Clin. Invest., 74 (1984) 906-913.
13. Friedman, R.M. and Vogel, S.N., Interferons with special emphasis on the immune system, Adv. Immunol., 34 (1983) 97-140.
14. Merimsky, O., Reider-Groswasser, I., Inbar, M. and Chaitchik, S., Interferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma, Eur. J. Cancer, 26 (1990) 596-600.
15. Meyers, C.A., Scheibel, R.S. and Forman, A.D., Persistent neurotoxicity of systemically administered interferon-alpha, Neurology, 41 (1991) 672-676.
16. Neff, N.H., Tozer, T.N. and Brodie, B.B., Application of steady-state kinetics to studies of the transfer of 5-hydroxyindoleacetic acid from brain to plasma, J. Pharmacol. Exp. Ther., 158 (1967) 214-218.
17. Pestka, S., Langer, J.A., Zoon, K.C. and Samuel, C.E., Interferons and their actions, Annu. Rev. Biochem., 56 (1987) 727-777.
18. Plata-Salamán, C.R., Interferons and central regulation of feeding, Am. J. PhysioL, 263 (1992) R1222-R1227.
19. Reddy, P.L., Khanna, S., Subhash, M.N., Channabasavanna, S.M. and Sridhara Rama Rao, B.S., CSF amine metabolites in depression, Biol. Psychiatry, 31 (1992) 112-118.
20. Renault, P.F., Hoofnagle, J.H., Park, Y., Mullen, K.D., Peters, M., Jones, D.B., Rustgi, V. and Jones, E.A., Psychiatric complications of long-term interferon alfa therapy, Arch. Intern. Med., 147 (1987) 1577-1580.
21. Rohatiner, A.Z.S., Prior, P.F., Burton, A.C., Smith, A.T., Balkwill, F.R. and Lister, T.A., Central nervous system toxicity of interferon, Br. J. Cancer, 47 (1983) 419-422.
22. Roy, A., Agren, H., Pickar, D., Linnoila, M., Doran, A.R., Cutler, N.R. and Paul, S.M., Reduced CSF concentrations of homovanillic acid and homovanillic acid to 5-hydroxyindoleacetic acid ratios in depressed patients: relationship to suicidal behavior and dexamethasone nonsuppression, Am. J. Psychiatry, 143 (1986) 1539-1545.
23. Roy, A., De Jong, J. and Linnoila, M., Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients: a 5-year follow-up study, Arch. Gen. Psychiatry, 46 (1989) 609-612.
24. Roy, A., Karoum, F. and Pollack, S., Marked reduction in indexes of dopamine metabolism among patients with depression who attempt suicide, Arch. Gen. Psychiatry, 49 (1992) 447-450.
25. Smedley, H., Katrak, M., Sikora, K. and Wheeler, T., Neurological effects of recombinant human interferon, Br. Med. J., 286 (1983) 262-264.
26. Talpaz, M., Kantarjian, H.M., McCredie, K., Trujillo, J.M., Keating, M.J. and Gutterman, J.U., Hematologic remission and cytogenetic improvement induced by recombinant human interferon alphaA in chronic myelogenous leukemia, N. Engl. J. Med., 314 (1986) 1065-1069.
27. Träskman, L., Åsberg, M., Bertilsson, L. and Sjöstrand, L., Monoamine metabolites in CSF and suicidal behavior, Arch. Gen. Psychiatry, 38 (1981) 631-636.
28. Willner, P., Dopaminergic mechanisms in depression and mania. In F.E. Bloom and D.J. Kupfer (Eds.), Psychopharmacology: The Fourth Generation of Progress, Raven, New York, NY, 1995, pp. 921-931.